Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators. West NE, et al. Among authors: beckett vv. J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29. J Cyst Fibros. 2017. PMID: 28457954 Free PMC article.
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group. Sanders DB, et al. Among authors: beckett vv. J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29. J Cyst Fibros. 2017. PMID: 28460885 Free PMC article.
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.
Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group. Heltshe SL, et al. Among authors: beckett vv. Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21. Contemp Clin Trials. 2018. PMID: 29170074 Free PMC article. Clinical Trial.
KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
Jain R, Beckett VV, Konstan MW, Accurso FJ, Burns JL, Mayer-Hamblett N, Milla C, VanDevanter DR, Chmiel JF; KB001-A Study Group. Jain R, et al. Among authors: beckett vv. J Cyst Fibros. 2018 Jul;17(4):484-491. doi: 10.1016/j.jcf.2017.12.006. Epub 2017 Dec 29. J Cyst Fibros. 2018. PMID: 29292092 Free article. Clinical Trial.
Neuroendocrine neoplasms: Consensus on a patient care pathway.
Hooper J, Jervis N, Morgan L, Beckett V, Hand P, Higgs K, Munir A, Prinn J, Pritchard DM, Sarker D, Srirajaskanthan R, Ellis CB. Hooper J, et al. Among authors: beckett v. J Neuroendocrinol. 2024 Apr;36(4):e13380. doi: 10.1111/jne.13380. Epub 2024 Mar 12. J Neuroendocrinol. 2024. PMID: 38471798 Review.
50 results